The global portal hypertension management market is predicted to be valued at US$ 3.05 billion in 2023, with a CAGR of 5% from 2023 to 2033. The market for portal hypertension management is expected to reach US$ 4.97 billion by the end of the forecast period. Currently, the generic pharmaceutical segment is leading the market, with a scope of diagnosis including vasopressin and its analogs, beta-blockers, and somatostatin and its analogs, indicating potential for medicinal study and development.
Cirrhosis is one of the primary causes of portal hypertension, and its increasing prevalence is expected to drive market expansion, particularly among the aging population. The National Institute of Diabetes and Digestive and Kidney Diseases reports that cirrhosis is more common in males than females. North America currently holds the largest market share due to high-cost technological innovations in the healthcare system and an increase in beta-blocker consumption. Meanwhile, Asia-Pacific is the second-largest market revenue due to its expanding elderly population and greater diagnosis percentage. In the next decade, North America is expected to continue to dominate the market due to the increasing incidence and occurrence of rare diseases, as well as the growing inpatient population.
For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16585
The Liver Transplantation segment is expanding due to the global rise in demand for transplantable organs. In 2019, the US Department of Health and Human Services reported approximately 122,913 diagnoses in the United States ready for organ transplants, leading to a high demand for developed transplantation products to intervene in organ damage. Consequently, the market for the Liver Transplantation segment is growing.
Key Takeaways from the Market Study
- From 2018 to 2022, sales witnessed major growth, registering a CAGR of 3%
- The global portal hypertension management market is predicted to garner a market value of US$ 4.97 Billion.
- Portal hypertension management market in North America is expected to grow at a CAGR of 4%
- Endoscopic therapy to be most preferred, expected to grow at a CAGR of 7%.
- The Asia Pacific market is expected to account for 40% of the market share.
“The therapies under advancement are focused on novel approaches to treating/improving disease signs. Companies involved are working on developing Portal Hypertension therapies. The launch of new treatments will have a significant impact on the portal hypertension management market.” says FMI’s analyst.
Last few days to get reports at discounted prices, offer expires soon!
Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16585
Competitive Landscape
Key players in the Portal Hypertension Management market are Ono Pharmaceutical Co., Ltd., Chiasma, Inc., Genextra S.p.a., Gilead Sciences, Inc., Debiovision, Inc., Govind Ballabh Pant Hospital, Dr. Falk Pharma GmbH, Novartis AG, Sun Pharmaceuticals Industries Ltd. Some recent developments by manufacturers are below
- In August 2022, ONO received approval in Japan for Onoact® for Intravenous Infusion 50mg/150mg (“Onoact”), a short-acting selective 1 blocker.
- In March 2021, Gilead Sciences announced that it would expand its collaboration with Novo Nordisk and gain knowledge of the prospects for composite strategies in helping patients with cirrhosis caused by NASH, contributing to the portal hypertension management market.
More insights available:
The European market is also significant, and it is expected to grow due to increasing awareness about liver diseases and advanced healthcare facilities. Moreover, favorable reimbursement policies are expected to further drive Portal Hypertension market growth in the region. The Asia-Pacific market is expected to show significant growth due to its expanding elderly population and greater diagnosis percentage. Increasing healthcare expenditure and rising awareness about liver diseases are expected to drive market growth in the region.
Customization Available@ https://www.futuremarketinsights.com/customization-available/rep-gb-16585
Key Segments Profiled in the Portal Hypertension Management Industry Survey
By Treatment:
- Liver Transplantation
- Endoscopic Therapy
- Banding
- Balloon Tamponade
- Shunting Procedures
- Nonsurgical Transjugular Intrahepatic Portal Systemic Shunt
- Surgical Shun
- Drug Class
- Octapeptides
- Cofactors
- PDE5 Inhibitor
- Beta Blockers
By End Users:
- Hospitals
- Specialty Clinic
- Others
About the Healthcare Division at Future Market Insights
The healthcare team at Future Market Insights offers expert analysis, time efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis on key trends including competitive landscape, profit margin, and research development efforts.
About Future Market Insights, Inc.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
